Sanitary reforms and AIDS health care indicators:comparison between two specialized remission services
DOI:
https://doi.org/10.17533/udea.rfnsp.275Keywords:
HIV infection, acquired immunodeficiency syndrome, program evaluation, health care reform, Colombia, health policyAbstract
Colombian health care reform (Sistema General de Seguridad Social en Salud, SGSSS) transformed public health system into an insurance model system. Objective: to compare health care in tworemission centers for HIV/AIDS control functioning before (centerA) and after (center B) SGSSS implementation. Materials and methods: retrospective study of all records collected by the two specialized centers between 1986 and 2002 (n = 1.252). Results: foreach service, indicators about reference, diagnosis, treatment, AIDSrisk, survival, lethality and effectiveness of HAART (highly activeanti-retroviral therapy) were obtained. Conclusions: some unfavorable conditions were identified in center B suggesting a worsening in interventions and operation continuity of the regional health care remission system. Those factors could be related toadministrative barriers —imposed by requirements of the new in-surance model— and they could explain patients’ seriousness atthe moment of remission.
Downloads
References
(1). Programa Conjunto de las Naciones Unidas sobre el VIH/Sida. Detener el sida: mantener la promesa. 2001. Gine-bra: ONUSIDA; 2001.
(2). Fischl MA, Richman DD, Grieco MH, et al. The efficacyof azidothymidine (AZT) in the treatment of patients withAIDS and AIDS-related complex. A double-blind, place-bo-controlled trial. N Engl J Med 1987;317(4):185-191. DOI: https://doi.org/10.1056/NEJM198707233170401
(3). Hammer SM, Squires KE, Hughes MD, et al. A contro-lled trial of two nucleoside analogues plus indinavir inpersons with human immunodeficiency virus infection andCD4 cell counts of 200 per cubic millimeter or less. N.Engl J Med 1997; 337(11):725-733.
(4). Centers for Disease Control and Prevention (CDC). Reportof the NIH panel to define principles of therapy of HIVinfection. MMWR 1998;47(RR-5):1-41.
(5). McMenamin J, Allardice G, Goldberg D, et al. Antiretro-viral combination therapy and HIV infection. Such treat-ment improved CD4 counts in Scottish patients. BMJ1998;317(7162):887. DOI: https://doi.org/10.1136/bmj.317.7162.887
(6). Hammer SM, Squires KE,Hughes MD, et al. A contro-lled trial of two nucleoside analogues plus indinavir inpersons with human immunodeficiency virus infection andCD4 cell counts of 200 per cubic millimeter or less. AIDSclinical trials group 320 study team. N Engl J Med1997;337(11):725-733. DOI: https://doi.org/10.1056/NEJM199709113371101
(7). McMenamin J, Allardice G, Goldberg D, et al. Op. cit.
(8). Egger M, Hirschel B, Francioli P, et al. Impact of newantiretroviral combination therapies in HIV infected pa-tients in Switzerland: prospective multicentre study. SwissHIV cohort study BMJ 1997;315(7117):1194-1199. DOI: https://doi.org/10.1136/bmj.315.7117.1194
(9). Sterne JA, Hernan MA, Ledergerber B, et al. Long-termeffectiveness of potent antiretroviral therapy in preven-ting AIDS and death: a prospective cohort study. Lancet2005;366(9483):378–384. DOI: https://doi.org/10.1016/S0140-6736(05)67022-5
(10). Cohen J. Therapies: confronting the limits of success.Science 2002;296(5577):2320-2324. DOI: https://doi.org/10.1126/science.296.5577.2320
(11). Colombia. Congreso. Ley 100 de 1993, diciembre 23, porla cual se crea el Sistema de Seguridad Social Integral yse dictan otras disposiciones. Bogotá: El Ministerio; 1993.
(12). Centers for Disease Control and Prevention (CDC).Guidelines for the uses of antiretroviral agents among HIV-infected adults and adolescents. [Sitio en internet]. Disponible en: http://www.cdc.gov/mmwr/preview/mmwrht-ml/rr5107a1.htm. Consultado: octubre de 2004.
(13). Centers for Disease Control and Prevention (CDC).Revision of the CDC surveillance case definition foracquired immunodeficiency syndrome. MMWR1987;36(Suppl 1S):1S-15S.
(14). Centers for Disease Control and Prevention (CDC). 1993revised classification system for HIV infection and expan-ded surveillance case definition for AIDS among adoles-cents and adults. MMWR 1992;41(RR-17):1-19.
(15). Gutiérrez M, Ospina S, Soto M, et al. Característicassociodemográficas y factores de riesgo para la infecciónpor VIH en usuarios de un servicio de asesoría. Antioquia1993-1996. Bol Epidemiol Antioq 1997;22:468-474.
(16). Velásquez G, Soto M, Ospina S, et al. Dinámica de lainfección por el virus de la inmunodeficiencia humana.Medellín, Colombia. Rev Panam Infectol 1999;3(1):4-9.
(17). Programa Conjunto de las Naciones Unidas sobre el VIH/Sida. Programas nacionales de sida. Guía para el moni-toreo y la evaluación. Ginebra: ONUSIDA; 2000.
(18). Organización Panamericana de la Salud, Programa Con-junto de las Naciones Unidas sobre el VIH/Sida. VIH ysida en las Américas: una epidemia multifacética. Was-hington, D.C.: OPS, ONUSIDA; 2001. p. 32-33.
(19). Rizzardi P, Pantaleo G. The immunopathogenesis of HIV-1 infection. En: Armstrong D, Cohen J. (Eds.) Infectiousdiseases. Londres: Mosby; 1999.
(20). Stephenson J. Survival of patients with AIDS depends onphysicians’ experience treating the disease. JAMA1996;275(10):745-746. DOI: https://doi.org/10.1001/jama.275.10.745
(21). Farmer P, Léandre F, Mukherjee J, et al. Community-basedapproaches to HIV treatment in resource-poor settings.Lancet 2001;358(9279):404-409. DOI: https://doi.org/10.1016/S0140-6736(01)05550-7
(22). Valdez H, Chowdhry T, Assad R, et al. Changing spec-trum of mortality due to human immunodeficiency virus:analysis of 260 deaths during 1995-1999. Clin Infect Dis2001;32(10):1487-1493. DOI: https://doi.org/10.1086/320164
(23). Jacobson LP, Li R, Phair J, et al.Evaluation of the effectiveness of highly active antiretroviral therapy in personswith human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epide-miol 2002;155(8):760-770. DOI: https://doi.org/10.1093/aje/155.8.760
(24). Velásquez G, Mejía P, Restrepo N, et al. Comportamien-to de la tuberculosis en pacientes infectados por el virusde inmunodeficiencia humana. Infectio 2000;4:32.
(25). Gayle HD, Hill GL. Global impact of human immunode-ficiency virus and AIDS. Clin Microbiol Rev2001;14(2):327-335. DOI: https://doi.org/10.1128/CMR.14.2.327-335.2001
(26). Tashima KT, Flanigan TP. Antiretroviral therapy in theyear 2000. Infect Dis Clin North Am 2000;14(4):827-849. DOI: https://doi.org/10.1016/S0891-5520(05)70136-7
(27). Hecht FM, Wilson AB, Wu AW, et al. Optimizing care forpersons with HIV infection. Ann Intern Med 1999;131(2):136-143. DOI: https://doi.org/10.7326/0003-4819-131-2-199907200-00011
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Gloria Velásquez, Rubén D. Gómez, Samuel A. Arias, Daniel C. Aguirre, Catalina Hoyos
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The contents of the articles are the responsibility of the authors
The editorial committee has editorial independence from the National School of Public Health "Héctor Abad Gómez" of the University of Antioquia.
The editorial committee is not responsible for aspects related to copying, plagiarism or fraud that may appear in the articles published in it.
When you are going to reproduce and disclose photographs or personal data in printed or digital format, informed consent is required. Therefore, this requirement is required of the author at the time of receipt of the manuscript.
Authors are responsible for obtaining the necessary permissions to reproduce any material protected by reproduction rights.
The authors preserve the moral rights and assign the economic rights that will correspond to the University of Antioquia, to publish it, distribute electronic copies, include them in indexing services, directories or national and international databases in Open Access, under the Creative Commons Attribution license -Not Commercial-Share Equal 4.0 International Commercial (CC BY-NC-SA) which allows others to distribute, remix, retouch, and create from the work in a non-commercial way, as long as the respective credit and license are granted. new creations under the same conditions.
The authors will sign the declaration of transfer of economic rights to the University of Antioquia, after the acceptance of the manuscript.
The editorial committee reserves the right to reject the articles whose authors do not offer satisfactory explanations about the contribution of each author, to meet the criteria of authorship in the submission letter. All authors must meet the four criteria of authorship according to ICMJE: "a) .- That there is a substantial contribution to the conception or design of the article or to the acquisition, analysis or interpretation of the data. b) That they have participated in the design of the research work or in the critical review of its intellectual content. c) .- That has been intervened in the approval of the final version that will be published.d). That they have the capacity to respond to all aspects of the article in order to ensure that issues related to the accuracy or integrity of any part of the work are adequately investigated and resolved. "
-- 
--
